Quarterly report · Q2
4005.TEDINET S100S4AB
Period2023-04-01 → 2023-09-30
Filed2023-11-07
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 60
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.19T | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥623.7bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥2.90T | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.53T | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥754.4bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | −¥133.7bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥61.9bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥60.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥5.7bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥103.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥53.9bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥231m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥126.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥13.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥76.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥43.2bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥81.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥11.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥107.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥55.9bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | −¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥73.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥12.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥4.38T | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥4.17T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.68T | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.83T | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.68T | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.55T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.49T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.89T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.70T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.22T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.17T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.38T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥277.7bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥305.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥486.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥365.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥115.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥111.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥83.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥79.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥19.4bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥140.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥178.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥24.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-46.69 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-26.41 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥4.27 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥49.58 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥6.77 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥4.27 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥49.57 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥6.77 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 27.9% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.1% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 29.5% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 123
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥76.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-07-01 → 2023-09-30 | ¥38.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥34.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-07-01 → 2023-09-30 | ¥17.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥41.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥21.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-07-01 → 2023-09-30 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥56.0bn |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥28.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥56.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥28.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥7.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | −¥3.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥159.8bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥80.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥149.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥76.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥393.1bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥199.4bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥390.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥197.9bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥44.4bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | −¥23.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥243.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥139.6bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥241.2bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥138.5bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7.6bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2023-07-01 → 2023-09-30 | −¥509m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥203.9bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥109.3bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥203.7bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥109.2bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥220m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥110m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥17.8bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥11.2bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥166.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥83.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥166.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥83.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥65.5bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | −¥32.2bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.17T |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥613.2bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.15T |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥606.1bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥14.7bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥7.0bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥93.1bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | −¥41.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥79.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-07-01 → 2022-09-30 | ¥47.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥37.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-07-01 → 2022-09-30 | ¥23.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥42.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥24.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥708m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥57.6bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥32.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥57.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥32.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥11.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥4.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥183.7bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥92.4bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥173.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥87.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥470.4bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥230.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥467.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥228.7bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥23.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥13.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥295.9bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥142.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥293.9bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥141.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥36.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥14.4bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥222.4bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥107.7bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥222.2bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥107.5bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥234m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥118m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥26.4bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥10.7bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥334.5bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥166.7bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥334.4bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥166.7bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥25.2bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥11.1bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.51T |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥739.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.49T |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥731.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥15.5bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥8.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥124.7bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥56.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,060
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | 197948000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 76505000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember | 109221000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | 138516000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember | 83942000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 606132000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 17600000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration | 623732000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | 1412000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 4426000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember | 110000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | 1071000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 7019000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 21154000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -28173000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration | － | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | 199360000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 80931000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember | 109331000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | 139587000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember | 83942000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 613151000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 38754000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -28173000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration | 623732000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember | -23375000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember | 3463000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember | 11177000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember | -509000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember | -32233000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_ReportableSegmentsMember | -41477000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1902000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -3494000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration | -43069000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-07 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第143期第２四半期(自 2023年７月１日 至 2023年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)住友化学株式会社 | |
| Company name in english cover page | FilingDateInstant | SUMITOMO CHEMICAL COMPANY, LIMITED | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 岩 田 圭 一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋二丁目７番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03(5201)0235 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 経理部長 山 内 利 博 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋二丁目７番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03(5201)0235 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 経理部長 山 内 利 博 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |